Clinical review: Update of avian influenza A infections in humans

被引：0
作者：
Christian Sandrock
Terra Kelly
机构：
[1] University of California,School of Medicine
[2] Davis,School of Veterinary Medicine
[3] University of California,undefined
[4] Davis,undefined
来源：
Critical Care | / 11卷
关键词：
Influenza; Acute Respiratory Distress Syndrome; Avian Influenza; Oseltamivir; Avian Influenza Virus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Influenza A viruses have a wide host range for infection, from wild waterfowl to poultry to humans. Recently, the cross-species transmission of avian influenza A, particularly subtype H5N1, has highlighted the importance of the non-human subtypes and their incidence in the human population has increased over the past decade. During cross-species transmission, human disease can range from the asymptomatic to mild conjunctivitis to fulminant pneumonia and death. With these cases, however, the risk for genetic change and development of a novel virus increases, heightening the need for public health and hospital measures. This review discusses the epidemiology, host range, human disease, outcome, treatment, and prevention of cross-transmission of avian influenza A into humans.
引用
收藏
相关论文
共 616 条
[81]  
Amonsin A(2001)Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals Antimicrob Agents Chemother 45 1216-1943
[82]  
Payungporn S(2004)Resistant influenza A viruses in children treated with oseltamivir: descriptive study Lancet 364 759-1215
[83]  
Noppornpanth S(2005)Oseltamivir resistance during treatment of influenza A (H5N1) infection New Engl J Med 353 2667-1737
[84]  
Wattanodorn S(2005)Avian flu: isolation of drug-resistant H5N1 virus Nature 437 1108-1220
[85]  
Theambooniers A(2005) and Antiviral Res 68 10-1351
[86]  
Tantilertcharoen R(2004) influenza virus inhibitory effects of viramidine J Infect 49 262-1739
[87]  
Englund L(2001)Medical treatment of viral pneumonia including SARS in immunocompetent adult Lancet 357 1937-373
[88]  
Klingeborn B(2005)Safety and antigenicity of non-adjuvanted and F59-adjuvanted influenza A/Duck/Singapore/97 (h5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza J Infect Dis 191 1210-undefined
[89]  
Mejerland T(2001)Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy Vaccine 19 1732-undefined
[90]  
Klingeborn B(2005)Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans J Infect Dis 191 1216-undefined
45678910111213